Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial

The phase III CHAARTED trial established upfront androgen-deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in overall survival (OS). Biological prognostic markers of outcomes and predictors of chemothe...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2021-09, Vol.32 (9), p.1157-1166
Hauptverfasser:	Hamid, A.A., Huang, H.-C., Wang, V., Chen, Y.-H., Feng, F., Den, R., Attard, G., Van Allen, E.M., Tran, P.T., Spratt, D.E., Dittamore, R., Davicioni, E., Liu, G., DiPaola, R., Carducci, M.A., Sweeney, C.J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen Antagonists - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use biomarker Decipher docetaxel Docetaxel - therapeutic use gene expression profiling Hormones - therapeutic use Humans Male metastatic prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!